

Results



RP 5307 Showed no CD 19 cell depletion at 1000 nM



RP 5307 Showed 1.35% CD20 cell depletion at 1000 nM

FIG. 1

Results




FIG. 2

Results




FIG. 3



Results
Daudi
RPMI-8226
U266B1
Raji
UBX + 1000 nM RP 5307
UBX
% Inhibition normalized
Concentration (ng/ml)
0.001
0.01
0.1
1
10
100
0
20
40
60
80
100
120
RP 5307-39.08% activity at 1000 nM
RP 5307-55.15% activity at 1000 nM
RP 5307-71.41% activity at 1000 nM
RP 5307-76.27% activity at 1000 nM

FIG. 4

U266B1– 72 h Incubation-RP 5307




FIG. 5

U266B1– 72 h UBX Anti CD20 Antibody




FIG. 6



U266B1– 72 h UBX + RP 5307(1000 nM)
Plot 3: Gated by: Gate 1
Count
Red Fluorescence (RED-HLIn)
M1
M2
M3
M4
CONTROL (DMSO)
100 ng/ml+ RP 5307
10 ng/ml + RP 5307
1 ng/ml + RP 5307
0.1 ng/ml + RP 5307
0.01 ng/ml + RP 5307
0.001 ng/ml + RP 5307

FIG. 7

Raji– 72 h Incubation-RP 5307




FIG. 8

Raji– 72 h UBX Anti CD20 Antibody




FIG. 9

Raji– 72 h UBX + RP 5307(1000 nM)




FIG. 10



TGR-1202 and Ublituximab Synergistically Activated Caspase 3 in the DLBCL Cell Line LY1
Caspase 3 activity
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
1
10
100
1000
10000
Ublituximab (UBX) (ng/ml)
UBX
combo
TG-1202 fixed 1uM

FIG. 11

TGR-1202 and Ublituximab Synergistically Activated Caspase 3 in the Burkitt Lymphoma Cell Line Raji




FIG. 12